India Pharma Outlook Team | Tuesday, 27 October 2026
Eris Lifesciences sees the injectable semaglutide market climbing from Rs 40-45 crore a month today to Rs 80-90 crore a month by next year.
Chairman and Managing Director Amit Bakshi shared this outlook while discussing the company’s Q2 performance, where diabetes therapies already contribute about 38 percent of total sales.
Its own brand Sundae, available in vials and pens, currently runs at a quarterly pace of Rs 16-18 crore.
The projection signals confident expansion in a high-growth therapy area rather than a simple restatement of recent numbers.
Eris reported operating revenue of Rs 892 crore in the quarter ended September, a 12.6 percent rise year-on-year. Net profit reached Rs 187 crore, up 39 percent. The diabetes segment grew 18.5 percent, ahead of the broader market’s 16.1 percent expansion.
Sundae sits firmly inside this stronger diabetes franchise. Most Indian generic versions of injectable semaglutide still rely on synthetic chemical processes, while the innovator uses recombinant DNA technology. Eris’s current sales therefore form a meaningful foothold in a competitive semaglutide market that continues to attract new entrants.
Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding
Management points to three clear forces that should lift the overall semaglutide market:
Eris already holds strong specialist relationships in the diabetes specialty segment. The company plans to strengthen that position further with an in-house recombinant semaglutide candidate.
It has received approval to conduct Phase 3 trials and intends to file the product from its Swiss Parenterals Unit II facility in Ahmedabad. In parallel, Eris will publish a study on visceral fat patterns among Indian patients. The findings should sharpen clinical understanding and support wider adoption of its formulations.
The path to Rs 80-90 crore monthly sales carries real challenges. Intense competition from other generics, ongoing pricing pressure, and the need to scale manufacturing and distribution all remain active constraints. Current volumes still represent a relatively small base compared with the overall diabetes market.
At the same time, Eris has rationalized its acute portfolio by licensing certain products to Zorvia Healthcare for a 7 percent royalty on net sales. The move frees management attention and capital for higher-growth chronic therapies, including the semaglutide market opportunity.
The Rs 80-90 crore monthly target for injectable semaglutide stands as an ambitious yet grounded near-term goal. It forms part of Eris’s broader shift toward high-growth chronic therapies, particularly the diabesity space.
Success will depend on disciplined execution around scale, clear differentiation through the recombinant platform, and sustained traction with specialists. The opportunity in the semaglutide market is evident; the degree of expansion will rest on how effectively the company converts that opportunity into consistent market share.
.jpg)
